‘Blood Products and the SWIFT trial for traumatic haemorrhage’ with Jason Smith

In this session we will examine the bleeding patient in the
tactical and combat environment. We will dig into some of the
fundamental education that has changed practice in recent years,
we will also examine the SWIFT Study which is a study of Whole
blood In Frontline Trauma A multi-centre randomised controlled
trial of the clinical and cost-effectiveness of pre-hospital
whole blood administration versus standard care for traumatic
haemorrhage.


To do this I am speaking with Surgeon Capt Jason
Smith. Jason is currently the Defence Professor of Emergency
Medicine at the Academic Department of Military Emergency
Medicine, Royal Centre for Defence Medicine, Birmingham. He was
also appointed Royal College of Emergency Medicine Professor in
2013, and is an Honorary Professor at Plymouth University
Peninsula Schools of Medicine and Dentistry. He was Consultant
Advisor in Emergency Medicine to the Medical Director General
(Navy) from 2010-2014. He is a Fellow of the Royal College of
Emergency Medicine, the Royal College of Physicians of London,
and the Royal Geographical Society. He undertook a doctorate in
the management of patients with blast lung injury, and his
current research interests include the treatment of pain in
emergency patients and the management of traumatic cardiac
arrest.


In the episode we examine:


Sequential approach to arresting bleeding

The utility of TXA

Pharmacological agents - TXA, FFP, FDP, blood, cryo-p,
RePHILL

The RePHILL trial

Pain mx and preferential agents

Freeze Dried Plasma and Fresh Frozen Plasma and part of the
array of intervention

The SWIFT trial



To find more on the SWIFT trial please see here:
https://www.nhsbt.nhs.uk/clinical-trials-unit/current-trials-and-studies/swift/





This podcast is brought to you in association with BHA Medical.
BHA medical source, supply and implement innovative medical
technology and solutions across the globe. BHA provide market
leading services in covid 19 testing kits, medical products,
smart technology and consultancy. One of the latest solutions
that BHA medical offer is the iMed end-to-end Covid-19 testing
and monitoring solution. NPH iMed is an end-to-end Covid-19
testing and monitoring solution, developed in partnership with
BHA Medical Limited to assist in collating and managing test
results, reopen travel, leisure, events and entertainment. One of
the first independent online test verification systems in the
world, NPH iMed is a leading solution for testing, managing and
monitoring all of your Covid-19 needs.


NPH Group has simplified the process of reporting test result
data for you through our online platform which makes capturing
the required data for submission easy, while easily recalling
individuals for repeat testing and submissions. NPH have created
a fully compliant and automatic upload capability, so you don’t
have to worry about it, with a cost-effective solution. More can
be found here:


https://bha-medical.com


https://www.bha-medical.com/imed-self-testing-monitoring-covid-19-app